Registration Deadline:
Explore other Industry Opportunities:
Gene Therapy
Novel Targets
- Novel targets for gene therapy [CNS disorders, peripheral diseases]
AAV-related technologies
- AAV capsid-related technologies
- Tissue-specific promoter and its screening method
- Technologies enhancing bystander effect in AAV gene therapy
- Technologies for evaluating behavior of AAV
- Techniques for evaluating in vivo delivery of gene therapy agents to muscle tissue
- Techniques that can quantitatively assess in vivo delivery of AAV capsids to muscle tissue in gene
Modality-related technologies
Target Protein Degrader・Molecular Glue
- Heterobifunctional protein degraders
- Novel methods for pairing POI and EP for rational discovery of molecular glue targeting CNS
Oligonucleotides
- Nucleic acid therapeutics with novel mechanism of action
- Technologies for modifying the behavior of oligonucleotides in organs and cells
RNA-targeting therapeutics
- Novel technologies for identifying functional RNA-targeting small molecules
Small-molecule library
- Technologies for constructing unique small-molecule libraries
- Development of AI system for compound management (solid weighing and liquid volume estimation)
Drug discovery technology
Informatics, AI technologies
- Research on protein binders utilizing AI/ML technologies
- Technology for predicting and selecting compounds with novel/desired bioactivity profiles using AI analysis of existing bioactivity data of small molecules
Platform technologies, Imaging
- In vitro amplification technologies for plasmid DNA
- Label-free technologies for evaluating the binding of small molecules to target proteins in cells
- Method for evaluating the turnover rate of endogenous proteins
- Imaging technologies for visualizing and analyzing intracellular dynamics of nanoparticles (e.g., LNPs, liposomes, nanomicelles)
- Labeling techniques for AAV capsids/siRNAs in PET/SPECT/fluorescent imaging
in vitro assay systems
- In vitro models for evaluating skin toxicities, vascular toxicities, or immune-mediated organ toxicities
- Novel in vitro evaluation models using iPSC-derived cells and patient-derived organoids
Extracellular Vesicles
- A high-throughput method for collection of EVs from high-volume plasma samples (>10 mL)
- Evaluation of tissue origin of EVs and selective isolation of tissue-specific EVs
Please note: Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.